Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSyncona Regulatory News (SYNC)

Share Price Information for Syncona (SYNC)

Share Price is delayed by 15 minutes
Get Live Data
99.00    0.00 (0.00%)
Bid:
98.90
Ask:
99.90
Spread: 1.00 (1.011%)
Market Cap: £602.11m
SYNC Live PriceLast checked at - London Stock Exchange

Intraday Syncona Share Chart

Proposed changes to expense arrangements

24 Nov 2015 10:40

BACIT LIMITED - Proposed changes to expense arrangements

BACIT LIMITED - Proposed changes to expense arrangements

PR Newswire

London, November 24

BACIT LIMITED(a closed-ended investment company incorporated in Guernseywith registration number 55514)

(the "Company")

24 November 2015

Proposed changes to expense arrangements

The Company announces a proposed change to the basis on which the operating expenses of BACIT (UK) Limited, the Company’s investment manager (the “Investment Manager”), are paid with effect from 1 January 2016. The proposed change is subject to shareholder approval. 

The key features of the Company’s investment policy — that it will invest in underlying funds on a “gross return” basis, that it will invest up to one per cent. per annum of its net asset value in drug development projects and that it will donate one per cent. per annum of its net asset value to charities including the Institute for Cancer Research (“ICR”) — will remain unchanged. Both the ICR and the managers of the underlying funds in which the Company currently invests are supportive of the proposed change. 

To date, neither the Investment Manager nor the BACIT investment management team have received a fee from the Company for their investment management services. Under the proposed arrangements, the personnel costs and operating expenses of the investment management function will be covered by a new fee payable by the Company to the Investment Manager equal to 0.19% per annum of the Company’s net asset value. It is not envisaged that the Investment Manager should make a meaningful profit from the fee. Notwithstanding the proposed changes to the expense arrangements Tom Henderson will continue to provide his services as a director of the Company and as CEO of the Investment Manager free of charge. 

A circular, including a notice of an extraordinary general meeting of the Company to approve the proposed changes to the expense arrangements intended to be held at 9.30 a.m. on 11 December 2015 at the offices of Northern Trust International Fund Administration Services (Guernsey) Limited, Trafalgar Court, Les Banques, St Peter Port, Guernsey GY1 3QL will be sent to shareholders shortly. 

A copy of the circular, when published, be available on the Company's website at http://www.bacitltd.com. The Circular will also be submitted to the National Storage Mechanism and will be available for inspection at www.morningstar.co.uk/uk/nsm.

Enquiries:

Northern Trust International Fund Administration Services (Guernsey) Limited

Tel: +44 (0) 1481 745368

Date   Source Headline
9th Jan 20257:00 amRNSTransaction in Own Shares
8th Jan 20257:00 amRNSTransaction in Own Shares
7th Jan 20257:00 amRNSTransaction in Own Shares
6th Jan 20257:00 amRNSTransaction in Own Shares
3rd Jan 20257:00 amRNSTransaction in Own Shares
2nd Jan 20252:44 pmRNSTotal Voting Rights
2nd Jan 20257:00 amRNSTransaction in Own Shares
31st Dec 20247:00 amRNSTransaction in Own Shares
30th Dec 20247:00 amRNSTransaction in Own Shares
27th Dec 20247:00 amRNSAchilles announces sale of technology assets
27th Dec 20247:00 amRNSTransaction in Own Shares
24th Dec 20247:00 amRNSTransaction in Own Shares
23rd Dec 20247:00 amRNSTransaction in Own Shares
20th Dec 20247:00 amRNSTransaction in Own Shares
19th Dec 20247:00 amRNSTransaction in Own Shares
18th Dec 20247:00 amRNSTransaction in Own Shares
17th Dec 20247:00 amRNSTransaction in Own Shares
16th Dec 20247:00 amRNSTransaction in Own Shares
13th Dec 20247:00 amRNSTransaction in Own Shares
12th Dec 20247:00 amRNSTransaction in Own Shares
11th Dec 202410:35 amRNSiOnctura presents clinical data update
11th Dec 20247:00 amRNSTransaction in Own Shares
10th Dec 20247:00 amRNSTransaction in Own Shares
9th Dec 20247:00 amRNSTransaction in Own Shares
6th Dec 202412:05 pmRNSBeacon announces clinical data update
6th Dec 20247:00 amRNSTransaction in Own Shares
5th Dec 20247:00 amRNSTransaction in Own Shares
4th Dec 20247:00 amRNSTransaction in Own Shares
3rd Dec 20247:00 amRNSTransaction in Own Shares
2nd Dec 20249:43 amRNSTotal Voting Rights
2nd Dec 20247:00 amRNSTransaction in Own Shares
29th Nov 20247:00 amRNSTransaction in Own Shares
28th Nov 20247:00 amRNSTransaction in Own Shares
27th Nov 20247:00 amRNSTransaction in Own Shares
26th Nov 20247:00 amRNSTransaction in Own Shares
25th Nov 20247:00 amRNSTransaction in Own Shares
22nd Nov 20247:00 amRNSTransaction in Own Shares
21st Nov 20247:00 amRNSTransaction in Own Shares
20th Nov 20247:00 amRNSTransaction in Own Shares
19th Nov 20247:59 amRNSBoard Committee Change
19th Nov 20247:00 amRNSTransaction in Own Shares
18th Nov 20247:00 amRNSTransaction in Own Shares
15th Nov 20247:00 amRNSTransaction in Own Shares
14th Nov 20247:00 amRNSSyncona launches Slingshot Therapeutics
14th Nov 20247:00 amRNSHalf-year Report
14th Nov 20247:00 amRNSTransaction in Own Shares
13th Nov 20247:00 amRNSTransaction in Own Shares
12th Nov 20241:18 pmRNSAutolus reports Q3 2024 Financial Results
12th Nov 20247:00 amRNSTransaction in Own Shares
11th Nov 20247:00 amRNSAutolus receives US FDA approval

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.